

《胰臟癌抗癌藥物治療指引》

115 年版與上一版差異

114 年版 修訂日 113/11/26	115 年版 修訂日 114/12/09
	審視無異動

《胰臟癌抗癌藥物治療指引》

Neoadjuvant Chemotherapy (±subsequent chemoradiation)

FOLFIRINOX

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Irinotecan	180	≥ 90 mins	d1	Q2W	4	1
Oxaliplatin	85	2 hrs	d1	Q2W	4	
Leucovorin	400	≥ 90 mins	d1	Q2W	4	
5-FU	400	5 mins	d1	Q2W	4	
5-FU	1200	22-24 hrs	d1-2	Q2W	4	

modified FOLFIRINOX

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Irinotecan	150 [#]	≥ 90 mins	d1	Q2W	4	2
Oxaliplatin	85	2 hrs	d1	Q2W	4	
Leucovorin	400	≥ 90 mins	d1	Q2W	4	
5-FU	1200	22-24 hrs	d1-2	Q2W	4	

[#] 團隊共識

Gemcitabine + Nab Paclitaxel

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 15	Q4W	2-4	3
Nab-Paclitaxel	125	≤ 30 mins	d1, 8, 15	Q4W	2-4	

Gemcitabine + Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8	Q3W	6	11
Cisplatin	35	≥ 90 mins	d1, 8	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8	Q3W	2	12
Cisplatin	60	≥ 2 hrs	d1	Q3W	2	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	800	30 mins	d1, 8	Q3W		13
Carboplatin	AUC 4	1 hr	d1	Q3W		

Only for known BRCA 1/2 or PALB2 mutation

Gemcitabine + Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 15	Q4W	2-6	4
Cisplatin	50	≥ 2 hrs	d1, 15	Q4W	2-6	

Adjuvant Chemotherapy

Preferred regimen

modified FOLFIRINOX

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Irinotecan	150	≥ 90 mins	d1	Q2W	12	5
Oxaliplatin	85	2 hrs	d1	Q2W	12	
Leucovorin	400	≥ 90 mins	d1	Q2W	12	
5-FU	1200	22-24 hrs	d1-2	Q2W	12	

Gemcitabine + Capecitabine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 5	Q4W	6	6
Capecitabine	750-1000* PO BID		d1-21	Q4W	6	

* 團隊共識

Other Recommended Regimen

Gemcitabine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 15	Q4W	6	6

5 Fu + Leucovorin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Leucovorin	20	5 mins	d1-5	Q4W	6	7
5-FU	425	5 mins	d1-5	Q4W	6	

Capecitabine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1000 PO BID	d1-14	Q3W	8	8

Gemcitabine + Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8	Q3W	2	12
Cisplatin	60	≥ 2 hrs	d1	Q3W	2	

Induction chemotherapy followed by chemoradiation**Gemcitabine based**

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 15	Q4W	2-6	9

5Fu + Leucovorin based

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Leucovorin	20	5 mins	d1-5	Q4W	6	9
5-Fu	425	5 mins	d1-5	Q4W	6	

Induction chemotherapy followed by chemoradiation followed by subsequent chemotherapy

Gemcitabine based

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 15	Q4-6W	1	10
Followed by radiation						
Gemcitabine	1000	30 mins	d1, 8, 15	Q4W	3-5	

5Fu + Leucovorin based

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Leucovorin	20	5 mins	d1-5	Q4W	1	10
5-Fu	425	5 mins	d1-5	Q4W	1	
Followed by CCRT						
Leucovorin	20	5 mins	d1-5	Q4W	3	
5-Fu	425	5 mins	d1-5	Q4W	3	

參考文獻

1. Murphy JE, et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018; 4:963-969.
2. Nanda RH, El-Rayes B, Maithel SK, et al. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol. 2015;111:1028-34.
3. Miyashita T, Tajima H, Makino I, et al. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts Through Depletion of Pancreatic Stroma. Anticancer Res. 2018; 38:337-343.

4. Oliver GR, Sugar E, Laheru D, et al. Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma. 2010 Gastrointestinal Cancers Symposium. Abstract No. 151.
5. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. *N Engl J Med* 2018;379:2395-2406.
6. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. *Lancet*. 2017;389:1011-1024.
7. Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. *JAMA*. 2012;308:147-56.
8. Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. *J Clin Oncol* 2002;20:160-164.
9. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma. a randomized controlled trial. *JAMA* 2008; 299:1019-1026.
10. Schellenberg D, Kim J, Christman-Skieller C, Chun CL, et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys*. 2011 Sep 1;81(1):181-8.
11. Cascinu S, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. *Lancet Oncol*. 2008;9(1):39–44. doi:10.1016/S1470-2045(07)70383-2
12. Lee KH, Chie EK, et al. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. *Cancer Res Treat*. 2021 Oct;53(4):1096-1103.
13. Xiros N, Papacostas P, et al. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. *Ann Oncol*. 2005 May;16(5):773-9. doi: 10.1093/annonc/mdi160. Epub 2005 Mar 31.

Locally Advanced or Metastatic Disease

First line therapy

Preferred Regimen

FOLFIRINOX (PS 0-2)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Irinotecan	180	≥ 90 mins	d1	Q2W	12	2
Oxaliplatin	85	2 hrs	d1	Q2W	12	
Leucovorin	400	≥ 90 mins	d1	Q2W	12	
5-FU	400	5 mins	d1	Q2W	12	
5-FU	1200	22-24 hrs	d1-2	Q2W	12	

modified FOLFIRINOX (PS 0-2)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Irinotecan	150 [#]	≥ 90 mins	d1	Q2W	2-8	2
Oxaliplatin	85	2 hrs	d1	Q2W	2-8	
Leucovorin	400	≥ 90 mins	d1	Q2W	2-8	
5-FU	1200	22-24 hrs	d1-2	Q2W	2-8	

[#] 團隊共識

NALIRIFOX (PS 0-1)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Liposomal Irinotecan	50	≥ 90 mins	d1	Q2W		20
Oxaliplatin	60	2 hrs	d1	Q2W		
Leucovorin	400	≥ 90 mins	d1	Q2W		
5-FU	1200	22-24 hrs	d1, 2	Q2W		

Gemcitabine + Nab Paclitaxel (PS 0-2)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 15	Q4W		3
Nab-Paclitaxel	125	≤ 30 mins	d1, 8, 15	Q4W		

Only for known BRCA 1/2 or PALB2 mutation**Gemcitabine + Cisplatin (PS 0-1)**

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 15	Q4W		1
Cisplatin	50	≥ 2 hrs	d1, 15	Q4W		
Followed by ± Olaparib	300 mg PO BID					10

Gemcitabine (PS 2-3)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 15	Q4W		5

Gemcitabine fixed-dosing-rate (10 mg/m²/min) (PS 3)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 15	Q4W		5

Capecitabine (PS 2-3)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1000 BID PO	d1-14	Q3W		14

Other Recommended Regimen

Gemcitabine + Erlotinib (PS 0-1)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 15	Q4W		4
Erlotinib	100-150 mg/day PO		d1-28	Q4W		

Gemcitabine (PS 0-1)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 15	Q4W		5

Gemcitabine + Capecitabine (PS 0-1)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 15	Q4W		15
Capecitabine	830 BID PO		d1-21	Q4W		

Capecitabine (not for metastatic disease) (PS 0-1)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1000 BID PO	d1-14	Q3W		14

Fix-dose-rate Gemcitabine, Docetaxel, Capecitabine (GTX) (PS 0-1)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	750	≥ 75 mins	d1	Q3W		16
Docetaxel	30	1 hr	d4, 11	Q3W		
Capecitabine	750 BID PO		d1-14	Q3W		

Gemcitabine + Nab-Paclitaxel + Cisplatin (PS 0-1)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8	Q3W		17, 18
Nab-Paclitaxel	125	≤ 30 mins	d1, 8	Q3W		
Cisplatin	25	≥ 30 mins	d1, 8	Q3W		

OFF (PS 0-1)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	2 hrs	d8, 22	Q6W	2-6	24
Leucovorin	200	≥ 90 mins	d1, 8, 15, 22	Q6W	2-6	
5-FU	2000	22-24 hrs	d1, 8, 15, 22	Q6W	2-6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	85	2 hrs	d1	Q2W		33
Leucovorin	400	≥ 90 mins	d1	Q2W		
5-FU	1200	22-24 hrs	d1-2	Q2W		

Gemcitabine + RT for local advanced disease

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	600	30 mins	d1	QW		34

CapeOx (≤ 65 years, ECOG 0-1) (PS 0-1)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	130	2 hrs	d1	Q3W		16
Capecitabine	1000 BID PO		d1-14	Q3W		

CapeOx (> 65 years or ECOG 2) (PS 2)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Oxaliplatin	110	2 hrs	d1	Q3W		16
Capecitabine	750 BID PO		d1-14	Q3W		

Not list in NCCN**GOLF (PS 0-1)**

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	90 mins	d1	Q2W		9
Oxaliplatin	85	2 hrs	d1	Q2W		
Leucovorin	120	≥ 90 mins	d1	Q2W		
5-FU	1200	22-24 hrs	d1-2	Q2W		

SOLG (PS 0-1)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	800	90 mins	d1	Q2W		13
Oxaliplatin	85	2 hrs	d1	Q2W		
Leucovorin	20 PO BID		d1-7	Q2W		
TS-1	20-40 PO BID		d1-7	Q2W		

Gemcitabine + Cisplatin/Carboplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8	Q3W	6	31
Cisplatin	35	≥ 1 hr	d1, 8	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	800	30 mins	d1, 8	Q3W		32
Carboplatin	AUC 4	1 hr	d1	Q3W		

Useful in Certain Circumstances

Larotrectinib NTRK gene fusion positive (PS 0-3)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Larotrectinib	100 mg PO BID				11

Entrectinib NTRK gene fusion positive (PS 0-3)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Entrectinib	600 mg PO QD				12

Repotrectinib NTRK gene fusion positive (PS 0-3)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Repotrectinib	160 mg PO*				25

*160 mg PO QD for 14 days followed by 160mg BID

Pembrolizumab only for MSI-H or dMMR (PS 0-3)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		8

Dabrafenib + Trametinib BRAF V600E mutation positive (PS 0-3)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Dabrafenib	150 mg PO BID	d1			22, 23
Trametinib	2 mg PO QD	d1			

Selpercatinib (if RET gene fusionpositive) (PS 0-2)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Selpercatinib	160 mg PO BID	d1			26

TS-1 (PS 2)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
TS-1	40-60 mg PO BID	d1-28*	Q6W*		6

*or on d1-14, Q3W

Metastatic Disease (maintenance therapy)

Preferred Regimen

If previous platinum-based chemotherapy:

Olaparib (only for germline BRCA1/2 mutations)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Olaparib	300 mg PO BID				27

Other Recommended Regimen

If previous first-line FOLFIRINOX:

Capecitabine

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Capecitabine	1000 PO BID	d1-14	Q3W		5

If previous first-line gemcitabine + nab-paclitaxel:

Gemcitabine (category 2B)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 15	Q4W		5

Gemcitabine + nab-Paclitaxel (category 2B)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8, 15	Q4W		21
nab-Paclitaxel	125	≤ 30 mins	d1, 8, 15			

Useful in Certain Circumstances

If previous first-line FOLFIRINOX:

5-FU + leucovorin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Leucovorin	200	≥ 90 mins	d1-2	Q2W		28
5-FU	400	5 mins	d1-2	Q2W		
5-FU	600	22-24 hrs	d1-2	Q2W		

5-FU + leucovorin + irinotecan (FOLFIRI)

藥品名	劑量 mg/m ²		給藥日	頻率	週期	參考文獻
Irinotecan	180	≥ 90 mins	d1	Q2W		29
Leucovorin	400	≥ 90 mins	d1	Q2W		
5-FU	400	5 mins	d1	Q2W		
5-FU	1200	22-24 hrs	d1-2	Q2W		

5-FU + leucovorin + oxaliplatin (FOLFOX)

藥品名	劑量 mg/m ²		給藥日	頻率	週期	參考文獻
Oxaliplatin	85	2 hrs	d1	Q2W		30
Leucovorin	400	≥ 90 mins	d1	Q2W		
5-FU	400	5 mins	d1	Q2W		
5-FU	1200	22-24 hrs	d1-2	Q2W		

Prior platinum-based therapy:**Rucaparib (for germline or somatic BRCA1/2 or PALB2 mutations)**

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Rucaparib	600 mg PO BID				19

For patients who did not have disease progression following their most recent platinum-based chemotherapy

參考文獻

1. Oliver GR, Sugar E, Laheru D, et al. Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma. 2010 Gastrointestinal Cancers Symposium. Abstract No. 151.
2. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011;364:1817-25.
3. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013;369:1691-703.
4. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol.* 2007;25:1960-6.
5. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol.* 1997;15:2403-13.
6. Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. *J Clin Oncol.* 2013;31:1640-8.
7. Gelibter A, Malaguti P, Di Cosimo S, et al. Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. *Cancer.* 2005;104:1237-45.
8. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. *J Clin Oncol.* 2020;38:1-10.
9. Gill S, Ko YJ, Cripps C, et al. PANCREOX: a randomized phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. *J Clin Oncol.* 2016; 34: 3914–3920.
10. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *N Engl J Med.* 2019;381:317-327.

11. Product Information: VITRAKVI(R) oral capsules, oral solution, larotrectinib oral capsules, oral solution. Loxo Oncology Inc (per FDA), Stamford, CT, 2018.
12. Product Information: ROZLYTREK(TM) oral capsules, entrectinib oral capsules. Genentech Inc (per FDA), South San Francisco, CA, 2019.
13. Chiang NJ, Tsai KK, Hsiao CF, et al. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. *Eur J Cancer*. 2020 Jan;124:123-130.
14. Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. *J Clin Oncol* 2002;20:160-164.
15. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. *J Clin Oncol* 2009;27:5513-5518.
16. Fine RL, Fogelman DR, Schreiber SM, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. *Cancer Chemother Pharmacol* 2008;61:167-175.
17. Jameson GS, Borazanci E, Babiker HM, et al. Response rate following albuminbound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: A phase 1b/2 pilot clinical trial [published online ahead of print, 2019 Oct 3] [published correction appears in *JAMA Oncol* 2019;5:1643]. *JAMA Oncol* 2019;6:125-132.
18. Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial. *JAMA Oncol* 2019;5:824-830.
19. Reiss KA, Mick R, O'Hara MH, et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. *J Clin Oncol* 2021;39:2497-2505.
20. Wainberg Z, Bekai-Saab T, Boland P, et al. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. *Eur J Cancer*. 2021 Jul;151:14-24.
21. Miyashita T, Tajima H, Makino I, et al. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts Through Depletion of Pancreatic Stroma. *Anticancer Res*. 2018; 38:337-343.

22. Salama AKS, Li S, Macrae ER, et al. Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. *J Clin Oncol* 2020;38:3895-3904.
23. Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, singlearm, multicentre basket trial. *Lancet Oncol.* 2020;21:1234-1243.
24. Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. *Eur J Cancer.* 2011 Jul;47(11):1676-81. doi: 10.1016/j.ejca.2011.04.011. Epub 2011 May 10. PMID: 21565490.
25. Solomon BJ, Drilon A, Lin JJ, et al. Repotrectinib in patients with NTRK fusionpositive advanced solid tumors, including non-small cell lung cancer: update from the phase 1/2 TRIDENT-1 trial. *Ann Oncol.* 2023;34:S787-S788.
26. Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. *Lancet Oncol.* 2022;23:1261-1273.
27. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *N Engl J Med.* 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387.
28. Dahan L, Phelip JM, Le Malicot K, et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: a randomized phase II trial (PRODIGE 35-PANOPTIMOX). *J Clin Oncol* 2018; 36(Suppl.): abstract 4000.
29. Franck C, Canbay A, et al., Maintenance Therapy with FOLFIRI after FOLFIRINOX for Advanced Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. *J Oncol.* 2019 Dec 6;2019:5832309. doi: 10.1155/2019/5832309.
30. Hecht JR, Lonardi S, et al., Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). *J Clin Oncol.* 2021 Apr 1;39(10):1108-1118. doi: 10.1200/JCO.20.02232. Epub 2021 Feb 8.

31. Cascinu S, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. *Lancet Oncol.* 2008;9(1):39–44. doi:10.1016/S1470-2045(07)70383-2
32. Xiros N, Papacostas P, et al. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. *Ann Oncol.* 2005 May;16(5):773-9. doi: 10.1093/annonc/mdi160. Epub 2005 Mar 31.
33. Kobayashi S, Tezuka S, Yamachika Y, et al. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study. *BMC Cancer.* 2023 Feb 21;23(1):177. doi: 10.1186/s12885-023-10654-3. PMID: 36809997; PMCID: PMC9945590.
34. Cardenes HR, Moore AM, Johnson CS, et al. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study. *Am J Clin Oncol.* 2011 Oct;34(5):460-5. doi: 10.1097/COC.0b013e3181e9c103.